Namodenoson (CF102), a synthetic small-molecule agonist, preferentially activates A3AR, modulating the PI3K/AKT, NF-kB, and Wnt signaling pathways, resulting in the apoptosis of HCC cells, and has demonstrated the ability to decrease HCC growth in preclinical tests [358]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.